PFE Valuation Metrics
PFE Stock Price Metrics
PFE Dividend Metrics
PFE Growth Rate Metrics
PFE Discounted Cash Flow Metrics
| Fair Value Price | $39.20 |
| Margin of Safety | 52.81% |
PFE Revenue Metrics
PFE PE Ratio Metrics
| PE Ratio | 19.58 |
| PE Ratio Avg TTM | 16.36 |
| PE Ratio Avg 3Y | 22.40 |
| Current VS TTM Avg | +19.68% |
| Current VS 3Y Avg | -12.58% |
| Current VS 5Y Avg | +7.70% |
PFE PS Ratio Metrics
| PS Ratio | 2.32 |
| PS Ratio Avg TTM | 2.32 |
| PS Ratio Avg 3Y | 2.45 |
| Current VS TTM Avg | +0.01% |
| Current VS 3Y Avg | -5.17% |
| Current VS 5Y Avg | -18.95% |
PFE PB Ratio Metrics
| PB Ratio | 1.63 |
| PB Ratio Avg TTM | 1.63 |
| PB Ratio Avg 3Y | 1.71 |
| Current VS TTM Avg | +0.19% |
| Current VS 3Y Avg | -4.70% |
| Current VS 5Y Avg | -30.77% |
PFE Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 15.50 |
| PFCF Ratio Avg TTM | 13.89 |
| PFCF Ratio Avg 3Y | 19.44 |
| Current VS TTM Avg | +11.55% |
| Current VS 3Y Avg | -20.25% |
| Current VS 5Y Avg | -3.48% |
PFE Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.78 |
| Debt/Equity Ratio Avg TTM | 0.77 |
| Debt/Equity Ratio Avg 3Y | 0.68 |
| Current VS TTM Avg | +1.30% |
| Current VS 3Y Avg | +15.56% |
| Current VS 5Y Avg | +23.48% |
PFE PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | - |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
PFE FCF Yield
| FCF Yield | 6.45% |
| FCF Yield Avg TTM | 7.35% |
| FCF Yield Avg 3Y | 5.93% |
| Current VS TTM Avg | -12.28% |
| Current VS 3Y Avg | +8.80% |
| Current VS 5Y Avg | -12.12% |
PFE Earnings Yield
| Earnings Yield | 5.11% |
| Earnings Yield Avg TTM | 6.28% |
| Earnings Yield Avg 3Y | 6.38% |
| Current VS TTM Avg | -18.64% |
| Current VS 3Y Avg | -19.94% |
| Current VS 5Y Avg | -31.48% |
PFE EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 14.13 |
| Ev/Ebit Ratio Avg TTM | 12.23 |
| Ev/Ebit Ratio Avg 3Y | 29.86 |
| Current VS TTM Avg | +15.55% |
| Current VS 3Y Avg | -52.68% |
| Current VS 5Y Avg | -39.57% |
PFE EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 12.38 |
| Ev/Ebitda Ratio Avg TTM | 10.50 |
| Ev/Ebitda Ratio Avg 3Y | 15.94 |
| Current VS TTM Avg | +17.89% |
| Current VS 3Y Avg | -22.35% |
| Current VS 5Y Avg | -9.93% |
PFE EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.01 |
| Ev/Assets Ratio Avg TTM | 1.00 |
| Ev/Assets Ratio Avg 3Y | 1.03 |
| Current VS TTM Avg | +1.02% |
| Current VS 3Y Avg | -1.93% |
| Current VS 5Y Avg | -21.23% |
PFE EV/Sales Ratio Metrics
| Ev/Sales Ratio | 3.31 |
| Ev/Sales Ratio Avg TTM | 3.30 |
| Ev/Sales Ratio Avg 3Y | 3.43 |
| Current VS TTM Avg | +0.38% |
| Current VS 3Y Avg | -3.39% |
| Current VS 5Y Avg | -8.90% |
PFE Current Ratio Metrics
| Current Ratio | 1.16 |
| Current Ratio Avg TTM | 1.17 |
| Current Ratio Avg 3Y | 1.11 |
| Current VS TTM Avg | -0.43% |
| Current VS 3Y Avg | +4.04% |
| Current VS 5Y Avg | -3.47% |
PFE Quick Ratio Metrics
| Quick Ratio | 0.87 |
| Quick Ratio Avg TTM | 0.90 |
| Quick Ratio Avg 3Y | 0.87 |
| Current VS TTM Avg | -2.79% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | -8.58% |
PFE ROIC Metrics
| ROIC | 8.84% |
| ROIC Avg 3Y | 10.60% |
| ROIC Avg 5Y | 10.43% |
| Current VS 3Y Avg | -16.62% |
| Current VS 5Y Avg | -15.27% |
| Current VS 10Y Avg | -5.28% |
PFE Return on Assets Metrics
| ROA | 3.73 |
| ROA Avg TTM | 3.75 |
| ROA Avg 3Y | 6.08 |
| Current VS TTM Avg | -0.40% |
| Current VS 3Y Avg | -38.68% |
| Current VS 5Y Avg | -47.30% |
PFE Return on Equity Metrics
| ROE | 8.99 |
| ROE Avg TTM | 9.04 |
| ROE Avg 3Y | 13.32 |
| Current VS TTM Avg | -0.55% |
| Current VS 3Y Avg | -32.49% |
| Current VS 5Y Avg | -44.07% |
PFE Net Profit Margin Metrics
| Net Profit Margin | 12.42% |
| Net Profit Margin Avg TTM | 12.51% |
| Net Profit Margin Avg 3Y | 14.97% |
| Current VS TTM Avg | -0.72% |
| Current VS 3Y Avg | -17.01% |
| Current VS 5Y Avg | -31.70% |
Last Updated: Wednesday, June 10, 2026
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla